2022 HIVMA Elections

Biographical Sketches and Personal Statements

HIVMA 2022 Elections Ballot

Vice Chair (4-year term): Colleen Kelley, MD, MPH

Atlanta, GA

Representative to the IDSA Board ofRajesh Gandhi, MD, FIDSA

Directors (3-year term):Boston, MA

Director (3-year term): Kathleen Jacobson, MD

Richmond, CA

Director (3-year term): Darrell McBride, DO

Danville, PA

Director (3-year term): Elizabeth Sherman, PharmD

Ft. Lauderdale, FL

Director (3-year term): Virginia Triant, MD, FIDSA

Boston, MA

Colleen F. Kelley, MD, MPH

Education: University of Florida, BS English, 1995; Emory University School of Medicine, MD, 2004; Emory University Rollins School of Public Health, MPH, 2004; University of California San Francisco, internal medicine residency, 2007; Emory University School of Medicine, infectious diseases fellowship, 2010; Board Certified in Internal Medicine, 2007; Board Certified in Infectious Diseases, 2009.

Primary Current Professional Activity: Associate professor of medicine, Emory University School of Medicine; associate professor of epidemiology (secondary appointment), Emory University Rollins School of Public Health; co-director for prevention sciences, Emory University Center for AIDS Research; program director, Emory Training Program in HIV Translational Research to End the Epidemic; affiliated scientist, Yerkes National Primate Research Center; investigator, HIV Prevention Trials Network; investigator, HIV Vaccine Trials Network; investigator, Coronavirus Prevention Network.

Other Relevant Activities/Appointments: IDWeek Program Committee, HIVMA representative, 2022-present; HIVMA Research Award, 2021; associate editor, *Open Forum Infectious Diseases*, 2021-present; Editorial Advisory Board, *Clinical Infectious Diseases*, 2020-present; HIVMA Board of Directors, 2017-2020; director, Case of the Week Clinical Conference, Division of Infectious Diseases, Emory University, 2013-present; author, 70 peer-reviewed manuscripts and other publications.

Personal Statement:

I immensely valued my time on the HIVMA Board of Directors from 2017 to 2020 and look forward to rejoining the leadership. As an HIV doctor practicing in the southern United States, I clearly saw the effects of poverty, lack of access to health care and a crumbling public health infrastructure. Through my HIVMA experience, I learned the critical importance of political advocacy and its real, positive effects on our profession and our patients. It has helped me to become a better HIV doctor, a better researcher and a better leader. The voice of HIVMA is a powerful force that continues to push the envelope in pursuit of health equity and justice for people affected by HIV. I look very much forward to listening to and learning from the other board members, HIVMA staff and community advocates. I know that, together, we will innovate solutions to difficult problems facing our HIV workforce, patients and community through advocacy and guidance to members. This is particularly critical in a post-COVID world where we are just beginning to understand the full effects of the pandemic on our clinical practices and systems and our patients and families. We have much work to do in eliminating health disparities, racism and xenophobia in health care. During my leadership tenure, I will help to elevate the voice of HIVMA members and ensure the ambitious HIVMA agenda continues to support the needs of its members and improve health for the patients we serve.

Representative to the IDSA Board of Directors

Rajesh T. Gandhi, MD, FIDSA

Education: Harvard Medical School, MD, 1990; intern and resident in internal medicine, Brigham and Women's Hospital, Massachusetts, 1990-1993; chief medical resident, Brigham and Women's Hospital, Massachusetts, 1994-1995; fellow in infectious diseases, Johns Hopkins Hospital, Maryland, 1998-2000.

Current Appointments: Professor of medicine, Harvard Medical School; director, HIV clinical services and education, Massachusetts General Hospital; co-director, Harvard University Center for AIDS Research.

IDSA Participation: I have had extensive experience with IDSA, serving in a variety of different roles. These include membership on the Education Committee and on the **ID**Week Program Committee. In the latter role, I interacted effectively with colleagues over several years to organize **ID**Week. I am also a member of the IDSA COVID-19 Treatment Guidelines Panel and have worked closely with IDSA leadership in that capacity. In addition, I have served on the HIVMA Board of Directors and as chair of HIVMA and am currently past chair of HIVMA. Through my service on the HIVMA board and as chair, I have experience interacting with IDSA leadership and have been involved with activities related to IDSA's work in global health, HIV and COVID-19. These experiences, and my broad perspective on the issues facing ID clinicians, researchers, and educators, will make me a deeply informed and effective member of the IDSA Board of Directors.

Scholarly Interests: HIV clinical research; COVID-19 therapeutics.

Other: HIVMA Clinician Educator Award; associate editor, *Clinical Infectious Diseases*.

Personal Statement: In addition to my formal roles within IDSA and HIVMA, I have had extensive experience in several focus areas for IDSA. In the area of research, I have been involved with HIV clinical research for several decades and have had leadership positions in the AIDS Clinical Trials Group. I am codirector of the Harvard Center for AIDS Research. I have also been active clinically in both outpatient infectious diseases care and hospital-based infectious diseases consultative care. I am the director of HIV clinical services and education at the Massachusetts General Hospital. My clinical expertise has been recognized by my selection for leadership positions in multiple clinical guidelines panels, including the DHHS HIV Antiretroviral Guidelines Panel, the IAS USA HIV Guidelines Panel, the NIH COVID-19 Treatment Guidelines Panel and the IDSA COVID-19 Treatment Guidelines Panel. I am also involved in ID education as deputy editor of *Journal Watch ID* and through several other initiatives. In these activities, I have demonstrated the ability to work collaboratively and effectively with others. I also have deep and well-informed insights into ID research, clinical care and education, which I would bring to the board. Finally, as chair of HIVMA and through my work on its board, I have experience with policy issues facing ID and HIV, and I would bring my perspective and experience on those policy issues to the board.

Kathleen Jacobson, MD

Education: California Polytechnic State University, BS Biochemistry, 1985; Loyola University Stritch School of Medicine, MD, 1992; Ventura County Medical Center Family Medicine Residency Program, Ventura, California, 1995; Ventura County Medical Center, self-designed HIV fellowship, 1997; Board-Certified in Family Medicine, 1993-present; American Academy of HIV Medicine, 2003-present, HIVMA HIV specialist, 2003-present.

Primary Current Professional Activity: Chief, STD Control Branch, California Department of Public Health; chair, California COVID-19 Testing Task Force, California Department of Public Health; consultant, Los Angeles Region Pacific AIDS Education and Training Center, University of California Los Angeles; medical officer, National Disaster Management Services, Assistant Secretary of Preparedness Response, United States Department of Health and Human Services, (April 2019-present).

Other Relevant Activities/Appointments: HIV consultant, Kern County Emergency Departments and Public Health Department (April 2019-present); consultant, University of Southern California Keck School of Medicine ED Testing and Treatment Expansion (October 2017-2020); Leadership Development Committee, IDSA/HIVMA (2019); senior HIV and TB care and treatment advisor to the country of Uganda, United States Centers for Disease Control and Prevention (October 2017-August 2018); associate professor of clinical family medicine, USC KSOM (August 1997-2020); medical school Year 2 course chair, Integrated Cases Section, USC KSOM (January 2001-September 2017); medical school year 3-4 course director, Family Medicine Clerkship, USC KSOM (July 2014-June 2016); medical school year 1 course clinical chair, Foundations of Medicine, USC KSOM (June 2010-June 2015); principal investigator, Expanded HIV Testing in Healthcare Settings Grant, California Department of Public Health (April 2015-December 2017); principal investigator, ED Treat ED Investigator Initiated Study, Gilead Medical Sciences (April 2017-March 2018); study principal investigator, Testing and Linkage to Care and PrEP CCTG 593 California Collaborative Treatment Group (April 2012-December 2018); study principal investigator, Incentivized Social Network Recruitment for HIV Case Finding, CCTG 596 California Collaborative Treatment Group (April 2012-December 2018); co-principal investigator, Rule Out HIV in the LAC USC ED, FOCUS (March 2011-February 2018); medical director, Los Angeles Regional Pacific AIDS Education and Training Center (June 2009-October 2017); regional clinical mentor, University of Washington for Namibia in Africa (August 2013-July 2014).

Personal Statement: By designing my own fellowship to train in HIV, my career began in workforce development. From there I joined the University of Southern California Keck School of Medicine Pacific AIDS Education and Training Center Program presenting regular HIV didactics, ultimately training a few thousand residents and health care providers including rural clinicians to ensure access to HIV care. As the medical director of the Los Angeles region PAETC, I developed and oversaw the training of an HIV fellowship. Frustrated by the frequently missed opportunities for HIV diagnosis in emergency departments, I spearheaded HIV testing, rapid treatment, linkage to care and PrEP in the largest ED in the western U.S. and expanded to multiple EDs. With the University of Washington, I spent a year in rural Namibia in Africa as the HIV/TB clinical mentor to health care providers in the one of the hardest hit regions globally for HIV/TB. As the senior HIV and TB care and treatment advisor for the United States CDC to the country of Uganda, I supported the delineation and uptake of new diagnostic algorithms and the education of the local CDC, Ministry of Health and academicians. My HIV work became the basis for my current roles ensuring testing and treatment access to those most impacted by COVID- 19 as the chair of the California COVID-19 Testing Task Force and for STDs as the chief of STD control. This hands-on work in HIV/COVID/STDs has given me an in-depth understanding of the challenges we face in HIV. I'm energetic, enthusiastic, innovative and would be honored to serve on the HIVMA Board of Directors to support initiatives focused on ensuring access for those most at risk for or impacted by HIV.

Darrell McBride, DO

Medical Education: Lake Erie College of Osteopathic Medicine, DO, 2012; Case Western University MetroHealth Medical Center, internal medicine residency, 2015; Washington University Barnes-Jewish Hospital, infectious diseases fellowship, 2018; Geisinger Medical Center, faculty, Division of Infectious Diseases, 2018-present.

Primary Current Professional Activity: Assistant professor of medicine; Division of Infectious Diseases at Geisinger Medical Center, program director of the Ryan White Program at Geisinger Medical Center; regional assistant dean of student affairs (Danville Campus) at Geisinger Commonwealth School of Medicine; co-chair of HIVMA: Ending HIV as an Epidemic Working Group.

Other Relevant Activities/Appointments: AIDS Resource Center Boards of Directors; co-chair of Black Outreach and Leadership Development Employee Resource Group; Regional Medical Education Committee; Clinical Education Subcommittee; Geisinger Diversity and Inclusion Council.

Personal Statement: I am interested in serving on the HIVMA Board to further engage on the policy and advocacy aspects of the fight to end the HIV epidemic. I am a dedicated HIV provider and truly believe in HIVMA's mission statement. Today, our minoritized populous is still disproportionally affected by HIV. The COVID-19 pandemic highlighted our medical inequities on a national scale, and we must actively assess how the social determinants of health can be mitigated moving forward. I believe this board can help address these issues in the realm of HIV. Understanding that we must end HIV in a two-pronged approach (HIV prevention + HIV treatment), it is time to focus heavily on the prevention end, until a cure is found. I have particular interest in HIV treatment and prevention in LGBTQIA and minority communities. If chosen, I promise to remain engaged, enthusiastic, and dedicated to the goals of the board. I hope to offer a perspective that will help decrease the HIV infection rate in the populations that need it the most.

Elizabeth Sherman, PharmD

Education: New College of Florida, BA biology, 2001; Nova Southeastern University College of Pharmacy, PharmD, 2007; The Brooklyn Hospital Center, PGY-1 pharmacy residency, 2008; University of California San Francisco, PGY-2 HIV pharmacy residency, 2009.

Primary Current Professional Activity: Associate professor of pharmacy practice, Nova Southeastern University College of Pharmacy; HIV clinical pharmacist and infectious disease fellowship faculty, Memorial Healthcare System Division of Infectious Disease; principal investigator, local partner site, South Florida – Southeast AIDS Education and Training Center.

Other Relevant Activities/Appointments: American Academy of HIV Medicine Florida Chapter Steering Committee, 2015-present; American Academy of HIV Medicine Credentialing Committee, 2011-present; Fundamentals of HIV Medicine author, 2021 ed., 2019 ed., 2017 ed.; HIV Pharmacotherapy: The Pharmacist's Role in Care and Treatment, section editor and author, 2018 ed.; Florida Department of Health, HIV/AIDS Section, AIDS Drug Assistance Program Committees, 2014-present; International Association of Providers of AIDS Care, Educational Planning Committee and abstract reviewer, 2014-present.

Personal Statement:

I am dedicated to confronting the HIV epidemic through strong partnerships and collaborations. Serving on the HIVMA Board will allow me the opportunity to effect this change at a national level. As an HIV clinical pharmacist and associate professor of pharmacy practice, I make strong contributions to the field of HIV care (particularly the key goals of bolstering the HIV workforce and promoting equitable access to care) – yet I know that it is through effective partnerships that we will continue to turn the tide of the HIV epidemic. As a College of Pharmacy faculty member, I lead HIV didactic education for the next generation of pharmacy providers. At my Ryan White HIV/AIDS Program-funded clinic, serving uninsured and underinsured patients living with HIV, I've introduced clinical pharmacy services to a multidisciplinary care team, maintain a collaborative research program and train pharmacy students, pharmacy residents and medical infectious disease fellows. I serve as principal investigator on funded projects for the AIDS Education and Training Center, where we train professionals of all capacities to provide quality HIV care. I am an effective academic trainer of health care professionals and trainees, an experienced clinical practitioner in HIV pharmacy and a leader in partnerships (such as AETC) that combat the HIV epidemic. I would be honored to serve as a board member because HIVMA's aims and priorities align directly with my professional mission.

Virginia (Jeanne) Triant, MD, MPH, FIDSA

Education: Harvard University, AB, 1996; Yale University School of Medicine, MD, 2002; Harvard School of Public Health, MPH, 2001; Brigham and Women's Hospital, internal medicine residency, 2005; Massachusetts General Hospital & Brigham and Women's Hospital, infectious diseases fellowship, 2008; Massachusetts General Hospital/Harvard Medical School, faculty, 2009-present.

Primary Current Professional Activity: Assistant professor of medicine, Harvard Medical School; associate physician, Massachusetts General Hospital Divisions of Infectious Diseases and General Internal Medicine.

Other Relevant Activities/Appointments: Fellow, IDSA; past chair for HIVMA, IDWeek Program Committee; participant in inaugural IDSA Leadership Institute; abstract reviewer, session moderator and presenter for IDWeek; mentor for IDWeek Mentorship Program and research mentor for medicine and infectious diseases residents and fellows; grant reviewer for Harvard University Center for AIDS Research and for NIH Special Emphasis Panels; recipient of grants on HIV and aging/comorbidities (American Heart Association and NIH K01, R21, R56 and two R01 awards).

Personal Statement: I would be honored to have the opportunity to serve on the HIVMA Board to help advocate for people living with HIV and advance the mission of HIVMA. I was drawn to infectious diseases and HIV medicine specifically for the opportunity to impact the health and well-being of people living with HIV at the individual level, through clinical care and education, and at the population level, through research and advocacy. My experience as an HIV clinician in the inpatient and outpatient settings and as a clinical researcher over the last decade has made me increasingly aware of the challenges that confront people living with HIV, particularly in my specific area of interest: HIV and aging. Working with multidisciplinary teams, I have sought to reduce disparities in the receipt of preventative care for chronic diseases by evaluating and developing new cardiovascular risk prediction models tailored to HIV. I have been grateful for opportunities to serve as the HIVMA chair for IDWeek and as a member of the IDSA Leadership Institute. In these roles, I have had the chance to work with and learn from colleagues from diverse backgrounds and settings to help delineate HIV-related educational, mentoring and workforce development goals. I am committed to advancing the priorities of HIVMA. I would bring an open mind, experience working with HIVMA and a passion for HIV clinical care and research to help achieve health equity for people living with HIVMA access to care, education, research and advocacy.